Omeros Corporation

Links: Y!

OMER / Message Board

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
2888	How ALXN is framing their compassionate use program for COVID-19	GN	flucurious		2	4/1/2020 4:33:02 PM

2887	Re: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation	GN	Biotech_Jim		2	4/1/2020 7:10:40 AM

2886	Re: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation	GN	flucurious		2	3/31/2020 8:54:11 PM

2885	Re: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation	GN	Sam1832		0	3/31/2020 8:01:33 PM

2884	Re: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation	GN	flucurious		5	3/31/2020 7:13:03 PM

2883	Re: IFRX doses first critical pneumonia patient in the Netherlands	GN	ulingt		1	3/31/2020 5:50:26 PM

2882	Re: IFRX doses first critical pneumonia patient in the Netherlands	GN	Biotech_Jim		0	3/31/2020 5:20:28 PM

2881	IFRX doses first critical pneumonia patient in the Netherlands	GN	smittyfrmpa		3	3/31/2020 4:35:39 PM

2880	Re: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation	GN	ChazCSP		1	3/31/2020 4:13:53 PM

2879	Re: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2- mediated complement over-activation	GN	Biotech_Jim		3	3/31/2020 7:45:27 AM


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement